These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 31342560

  • 1. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
    Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF.
    J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
    [Abstract] [Full Text] [Related]

  • 2. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 5. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
    Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M.
    J Eur Acad Dermatol Venereol; 2021 Jan 25; 35(1):135-142. PubMed ID: 32365251
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN.
    Br J Dermatol; 2019 Jun 25; 180(6):1348-1351. PubMed ID: 30632140
    [Abstract] [Full Text] [Related]

  • 13. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    López Jiménez P, Suárez Pérez J, Herrera Acosta E, Aguilera Arjona J, Mendiola Fernández MV, Bosch García R, Herrera Ceballos E.
    Dermatol Ther; 2019 Jul 25; 32(4):e12937. PubMed ID: 30983098
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study.
    Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V.
    J Manag Care Spec Pharm; 2018 Jul 25; 24(7):617-622. PubMed ID: 29952701
    [Abstract] [Full Text] [Related]

  • 16. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
    Alpalhão M, Duarte J, Diogo R, Vandemeulebroecke M, Ortmann CE, Kasparek T, Filipe P.
    BioDrugs; 2022 Nov 25; 36(6):781-789. PubMed ID: 36334236
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C, JUNCTURE study group.
    J Eur Acad Dermatol Venereol; 2015 Jun 25; 29(6):1082-90. PubMed ID: 25243910
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.